| Review on clinical strategies for managing patients with elevated Lp (a): Cost-effectiveness of Lp (a) testing and awareness of lifestyle changes via Public Health Policy in … P Orfanos, X Hu, G Montgomery, C Abbas, L Lymperopoulou, N Bennett, ... European Journal of Cardiovascular Nursing 22 (Supplement_1), zvad064. 121, 2023 | 1 | 2023 |
| Elevated lipoprotein (a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from … P Welsh, A Al Zabiby, H Byrne, HR Benbow, T Itani, G Farries, ... Atherosclerosis 389, 117437, 2024 | | 2024 |
| EPH58 The Risk of First and Recurrent Mace Associated with Elevated Lp (A) in a Primary Prevention Population H Benbow, A Al Zabiby, H Byrne, M Costa Value in Health 26 (12), S213, 2023 | | 2023 |
| Increased Risk of Major Adverse Cardiovascular Events Attributed to Lipoprotein (a) Across Current Atherosclerotic Cardiovascular Disease Risk Categories H Benbow, A Al Zabiby, X Hu, H Byrne, M Costa-Scharplatz Circulation 148 (Suppl_1), A14601-A14601, 2023 | | 2023 |
| The burden of coronary revascularization associated with lipoprotein(a) in patients with atherosclerotic cardiovascular disease: data from the UK Biobank NS P Welsh, H Byrne, M Costa-Scharplatz, A F Fonseca, T Itani, G Farries, A ... European Heart Journal 43 (Issue Supplement_2), 2022 | | 2022 |
| The association of lipoprotein(a) with mace including coronary revascularisations in patients with atherosclerotic cardiovascular disease: Data from UK Biobank NS P.I. Welsh, R. Brown, A.F. Fonseca, G.Farries, T.Itani, A. Al Zabiby, S ... Atherosclerosis 355, Page 41, 2022 | | 2022 |
Naveed SattarUniversity of GlasgowVerified email at glasgow.ac.uk
